As drug makers jockey for their share of the fast-growing hepatitis C market, the deal between Johnson & Johnson JNJ -0.35% and Achillion Pharmaceuticals ACHN -15.26% has Wall Street analysts rethinking forecasts.
The deal, which was announced late yesterday after a Twitter rumor had Gilead Sciences GILD -0.35%
buying Achillion, calls for J&J to invest $225 million and assume
responsibility for development costs. Ultimately, the value of the
agreement could reach $1.1 billion, depending on milestones reached.
For J&J, the move may help reposition the company as a player in
the hepatitis C market. And for Achillion, the collaboration provides a
deep-pocketed partner for a company that some saw as a buyout target.
But to what extent will this transform the hepatitis C market and what
are the implications for the other drug makers? Here are what some of
the wags are saying…
Labels: achillion, collaborations, Janssen